New Investment into Pharmaron Positions the Company for Future Growth

Pharmaron, a fully integrated CRO, today announced that the company reached a definitive agreement with a consortium led by CITIC M&A Fund and Legend Capital for an investment of over US$280 million in the company, capitalizing Pharmaron for its future growth and allowing certain shareholders to realize significant gains on their earlier investments.

The company plans to use the funding to further strengthen its core R&D service platforms to significantly expand its existing R&D capabilities and capacity and to adopt new and cutting-edge technology to better serve its partners and customers in advancing their drug R&D programs.

“Pharmaron’s goal is to help our partners and customers succeed in their drug R&D programs.” said Boliang Lou, PhD, Chairman and Chief Executive Officer of Pharmaron. “We are delighted to have CITIC M&A Fund and Legend Capital as our lead investors as they share Pharmaron’s long-term vision. Their investment is a reflection of their long-term commitment and a demonstration of confidence in our business. The capital and expertise they bring to Pharmaron will ensure our ability to continue to expand our service offerings and footprint domestically and internationally, as we become a global leader in the small-molecule drug R&D services industry.”

Richard Li, Managing Director of Legend Capital, said, “Being one of the first institutional investors in Pharmaron, over the past 8 years we have witnessed the growth and achievement of Pharmaron and believe the company is well positioned to become a global leader in the drug R&D services industry. With the increased demand for innovative drug products in China, Pharmaron’s international track record and deep Chinese roots uniquely position them to serve the booming and innovative drug R&D community in China.”

Yongwu Fan, PhD, President and Managing Director of CITIC M&A Fund, said, “We are thrilled to have the opportunity be a lead investor in Pharmaron. CITIC M&A Fund sees strong growth prospects for the drug R&D services industry globally, as well as in China. We are extremely impressed with Pharmaron’s scientific depth and service-oriented culture, which have been the key drivers for Pharmaron’s success in the past and will continue to be in the future. We believe in Pharmaron’s long-term vision and are looking forward to working together to continuously create value for Pharmaron’s customers and shareholders. CITIC M&A Fund will bring our capital markets expertise and resources to help ensure Pharmaron’s continued success and strong growth.”

Teneo Capital served as financial advisor to Pharmaron in the transaction; O’Melveny & Meyers LLP and Zhong Lun Law Firm served as Pharmaron’s legal advisors.

About Pharmaron

Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2003, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology and toxicology to chemical & pharmaceutical development. With over 3,000 employees and operations in China and the U.S., Pharmaron has an excellent track record in the delivery of R&D solutions for its partners in North America, Europe, Japan and China. For more information, please visit www.pharmaron.com.

Contact

Katherine Lee, Senior Vice President of Strategic Partnerships

klee@pharmaron.com

 

康龙化成达成新一轮融资项目最终协议,公司发展进入快速通道

康龙化成今天宣布新一轮融资项目达成最终协议。此次融资以中信并购基金和君联资本为主导,总额为2.8亿美元,为公司进一步深化发展提供资金保证。通过此次融资,允许部分股东变现,作为他们早期投资的丰厚回报。

公司计划利用此项资金进一步加强战略性研发服务领域的建设,大幅增强研发能力, 提高研发容量,拓宽服务领域,利用尖端技术和高科技平台为合作伙伴和客户提供更优质的研发服务,共同提高新药研发效率。

“康龙化成的宗旨是以最高水平的研发服务,帮助伙伴们成功开发新药,降低新药研发成本,提高新药研发效率。”康龙化成董事长兼CEO楼柏良博士说道:“我们很高兴中信并购基金和君联资本能成为我们的主要投资人,非常感谢他们的信任及长期承诺。我们拥有共同的长期愿景,此次投资有利于我们深化服务及全球业务拓展,为中国及全球医药行业提供更优质的服务,成为小分子药物研发服务领域的全球领袖。”

君联资本执行董事李家庆表示:“作为康龙化成最早的风投机构之一,在过去的八年中,我们亲眼见证了该公司的发展和所取得的光辉成就。扎根中国,励精图治,积累了良好的国际声誉,获得业界的广泛认可。随着我国创新药需求的增加,我想康龙化成已做好准备,迎接中国创新药研发领域的蓬勃发展。”

中信并购基金总经理范永武博士表示:“我们很高兴成为康龙化成的主要投资人。中信并购基金看好医药研发服务在全球范围内和中国的长期增长趋势。康龙化成严谨的科学态度和浓郁的科研氛围,给我们留下了深刻印象,这是康龙化成过去取得成功的关键因素之一,并将继续指引未来。对于康龙化成的长期愿景我们深表赞同,并愿为之付出不懈努力,为客户和股东创造更加优秀的市场价值。中信并购基金携手康龙化成共同发展,将利用自身在资本市场的优势,助力企业实现飞跃成长。”

Teneo 资本担任此次交易的财务顾问,美迈斯律师事务所和中伦侓师事务所担任法律顾问。

关于康龙化成

康龙化成新药技术有限公司(非上市企业),成立于2003年,是国际领先的生命科学研发服务企业。公司宗旨为“以最高水平的研发服务,帮助伙伴们成功开发新药,降低新药研发成本,提高新药研发效率”,经过多年发展,打造了全方位的临床前药物研发一体化平台,贯穿合成化学与药物化学、生物、药物代谢及药代动力学、药理、毒理、药品开发等各个领域。在中国及美国两地拥有员工3000多人,一流的人才队伍,高质量的研发服务,获得业界广泛认可,与北美、欧洲、日本和中国的各医药公司/机构保持长期、稳固的合作关系。详情请访问公司网站:www.pharmaron.com

如欲了解更多信息,请联系:

Katherine Lee女士

高级副总裁,战略合作

klee@pharmaron.com